6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-04-15), Gain Therapeutics's 6-1 Month Momentum % is -12.08%.
The industry rank for Gain Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
GANX's 6-1 Month Momentum % is ranked better than 54.19% of 1469
companies
in the Biotechnology industry
Industry Median: -13.2
vs GANX: -12.08
Competitive Comparison of Gain Therapeutics's 6-1 Month Momentum %
For the Biotechnology subindustry, Gain Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gain Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gain Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Gain Therapeutics's 6-1 Month Momentum % falls into.
Gain Therapeutics (NAS:GANX) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gain Therapeutics (NAS:GANX) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Gain Therapeutics 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Gain Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GANX has been successfully added to your